We shall see. Interim analysis could be concluded in Q1. See whether we need a second in Fall. More drugs pending approval than $ONTY.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
